CA2716223A1 — Pyrrolopyrazine kinase inhibitors
Assigned to F Hoffmann La Roche AG · Expires 2009-09-03 · 17y expired
What this patent protects
The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula (I), wherein the variables Q1 and R are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and in-flammatory diseases.
USPTO Abstract
The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula (I), wherein the variables Q1 and R are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and in-flammatory diseases.
Drugs covered by this patent
- Zelboraf (vemurafenib) · Hoffmann La Roche
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.